[New forms of hormonal contraception].
Among new forms of hormonal contraception, three interesting exemples are described with a high level of effectiveness and low dosage regimen that allow improved safety and tolerance: a very low-dose estrogen-progestogen combination of ethinylestradiol and gestodene for 24-day cyclical administration; a progestogen-alone subcutaneous implant containing etonogestrel; and a levonorgestrel-releasing intrauterine system. These preparations appear to be particularly interesting as they provide additional possibilities for individualizing contraceptive therapy.
Gaspard
U
U
Service de Gynécologie, CHU Sart Tilman B 35, Université de Liège, 4000 Liège 1, Belgique.
Buicu
C
C
van den Brûle
F
F
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D017135:Desogestrel; D004343:Drug Implants; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007434:Intrauterine Devices; D016912:Levonorgestrel / Q000008:administration & dosage; D009652:Norpregnenes / Q000008:administration & dosage; D014753:Vinyl Compounds / Q000008:administration & dosage
D003271:Contraceptive Agents, Female; D003277:Contraceptives, Oral, Combined; D004343:Drug Implants; D009652:Norpregnenes; D014753:Vinyl Compounds; C033273:Gestodene; C044815:etonogestrel; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; D017135:Desogestrel